Over the past twenty years, anti-HER2 therapies such as trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1) revolutionized the treatment landscape of resectable HER2-overexpressing breast cancers [2,3,4]. The gene discussed is ERBB2; the disease is breast carcinoma.